ViiV’s long-acting HIV injectable Cabenuva preferred over Biktarvy by 90% of patients in PhIII trial

Most HIV patients in a Phase III study investigating ViiV Healthcare’s long-acting injectable Cabenuva and Gilead Sciences’ daily pill Biktarvy preferred the injection over the pill, citing a range of physical and emotional benefits.

Patients also reported improved adherence to the medication and emotional and psychological benefits.

ViiV said Monday…
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks